SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT04362644

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

The purpose of the study is to see if imaging with [18F]FDG and [18F]DPA-714 using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

NCT04362644 Idiopathic Pulmonary Fibrosis
MeSH:Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

1 Interventions

Name: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714

Description: Study participants will undergo PET/CT with the glucose analogue [F-18]FDG and the TSPO ligand [F-18]DPA-714 in two separate imaging sessions.
Type: Drug
Group Labels: 5

PET/CT using PET ligands [18F PET/CT using PET ligands [18F] PET/CT using PET ligands [18F]FDG and [18F PET/CT using PET ligands [18F]FDG and [18F] PET/CT using PET ligands [18F]FDG and [18F]DPA-714


Primary Outcomes

Measure: Correlate quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests.

Time: screening to 48 hours post 2nd imaging visit.

Purpose: Diagnostic

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 rs6971

4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70. 5. High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971.

Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.



HPO Nodes


HPO: